Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822395 | 0.92 | MAOB (0.36) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL9374944 | 0.91 | MAOB (0.39) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL4815068 | 0.90 | MAOB (0.34) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL4819923 | 0.87 | MAOB (0.31) | MAOBMAOAACHE | |
| SCHEMBL4819430 | 0.87 | MEN1 (0.31) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL9870275 | 0.85 | MAOB (0.38) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL29664175 | 0.85 | GAA (0.42) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL78795 | 0.85 | GAA (0.42) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL4824520 | 0.83 | MAOB (0.40) | MAOBMAOAKMT2AMEN1ACHE | |
| SCHEMBL1896797 | 0.82 | MAOB (0.42) | MAOBMAOAKMT2AMEN1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030074833-A1 | Benzotriazole/hals molecular combinations and compositions stabilized therewith | CIBA SPECIALTY CHEMCIALS CORP. | 2003-04-24 | — | — | US | claimed |
| WO-2002079173-A1 | BENZOTRIAZOLES AND THEIR USE AS UV LIGHT STABILISERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-10-10 | — | — | WO | claimed |
| US-7419513-B2 | Hindered amine light stabilizers (HALS); for thermoset/thermoplastic resins, photographic applications, pigmented/dyed polypropylene, polyamide/polyester fibers, and for white, dyed, dipped, unscented/scented candle wax against discoloration and fading | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050043543-A1 | Benzotriazole/HALS molecular combinations and compositions stabilized therewith | WOOD MERVIN G (US) | 2005-02-24 | — | — | US | disclosed |
| US-6846929-B2 | Benzotriazole/hals molecular combinations and compositions stabilized therewith | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030074833-A1 | Benzotriazole/hals molecular combinations and compositions stabilized therewith | CIBA SPECIALTY CHEMCIALS CORP. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030074833-A1 | Benzotriazole/hals molecular combinations and compositions stabilized therewith | TAS1R1, TAS1R2, BRWD1 | MAOB 972/4885MAOA 697/4885KMT2A 416/4885 |
| US-20050043543-A1 | Benzotriazole/HALS molecular combinations and compositions stabilized therewith | BRWD1, TAS1R2, TAS1R1 | MAOB 787/4885MAOA 690/4885KMT2A 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.